Kostev Karel, Lang Martina, Tröbs Sven-Oliver, Urbisch Sophia, Gabler Maximilian
IQVIA, Epidemiology, 60549 Frankfurt am Main, Germany.
University Hospital, Philipps University of Marburg, 35043 Marburg, Germany.
Medicina (Kaunas). 2025 May 2;61(5):843. doi: 10.3390/medicina61050843.
The underdiagnosis of chronic kidney disease (CKD) is a critical issue worldwide. This present study aimed to explore the CKD subpopulation regarding underdiagnosed CKD in individuals with a pathological estimated glomerular filtration rate (eGFR) and/or urine albumin-creatinine ratio (UACR) values in Germany. This analysis used data from the IQVIA Disease Analyzer database and included adult outpatients with at least two pathological consecutive eGFR and/or UACR values, documented at least 60 days apart between October 2018 and September 2023 in 758 general practices. According to the 2024 KDIGO clinical practical guidelines, CKD was defined based on both eGFR and UACR values. UACR values were used when no pathological eGFR values were documented. The main outcome of the study was the proportion of patients with a documented CKD in the total population as well as in defined subgroups. A total of 113,996 CKD patients (mean age: 76.5 (SD: 10.1) years; 60.2% female; 71.5% with mildly to moderately, 21.1% with moderately to severely, and 4.6% with a severely decreased eGFR value; and 1.0% with end-stage kidney disease) were available for analyses. CKD diagnosis was documented in 46.9% of CKD patients and was more frequent in male than in female patients (53.3% versus 42.7%). The highest proportion was observed in patients with heart failure (57.0%), followed by patients with type 2 diabetes (52.7%). In patients without diabetes and heart failure, CKD was documented in 38.2%. The proportion of CKD diagnoses increased with decreasing eGFR values, from 22.0% in patients with nonpathological eGFR but moderately or severely increased UACR to 87.7% in patients with end-stage kidney disease. The study provides valuable insights into the subpopulation of underdiagnosed CKD patients among a large patient population. These results underscore the need for improved screening, timely diagnosis documentation, and treatment strategies for CKD, particularly among high-risk populations. Moreover, it raises the need to increase awareness of micro- and macroalbuminuria as diagnostic criteria for CKD independent of eGFR.
慢性肾脏病(CKD)的诊断不足是一个全球性的关键问题。本研究旨在探讨德国具有病理估计肾小球滤过率(eGFR)和/或尿白蛋白肌酐比值(UACR)值的个体中未被诊断出的CKD亚群。该分析使用了IQVIA疾病分析仪数据库的数据,纳入了758家普通诊所中在2018年10月至2023年9月期间至少有两个连续病理eGFR和/或UACR值且记录间隔至少60天的成年门诊患者。根据2024年KDIGO临床实践指南,CKD基于eGFR和UACR值进行定义。当未记录到病理eGFR值时使用UACR值。该研究的主要结果是在总人口以及特定亚组中有记录的CKD患者比例。共有113,996例CKD患者(平均年龄:76.5(标准差:10.1)岁;60.2%为女性;71.5%的患者eGFR轻度至中度降低,21.1%的患者eGFR中度至重度降低,4.6%的患者eGFR严重降低;1.0%的患者患有终末期肾病)可供分析。46.9%的CKD患者有CKD诊断记录,男性患者的诊断记录比女性患者更频繁(53.3%对42.7%)。在心力衰竭患者中观察到的比例最高(57.0%),其次是2型糖尿病患者(52.7%)。在无糖尿病和心力衰竭的患者中,有CKD诊断记录的比例为38.2%。CKD诊断比例随着eGFR值的降低而增加,从非病理eGFR但UACR中度或重度升高的患者中的22.0%增加到终末期肾病患者中的87.7%。该研究为大量患者群体中未被诊断出的CKD患者亚群提供了有价值的见解。这些结果强调了改善CKD筛查、及时诊断记录和治疗策略的必要性,特别是在高危人群中。此外,它还提出了提高对微量和大量白蛋白尿作为独立于eGFR的CKD诊断标准的认识的必要性。